近日，Soleno Therapeutics 宣布，美国 FDA 已批准 VYKAT XR（二氮嗪胆碱，Diazoxide choline）缓释片上市，用于治疗患有普拉德-威利综合征（PWS）的成人和 4 ...

Diazoxide choline is the first drug indicated for hyperphagia in the rare genetic disorder. Prior to approval, people with ...

The FDA has approved Vykat XR (diazoxide choline) for the treatment of hyperphagia in adults and pediatric patients 4 years ...

The FDA has approved the first therapy to address hyperphagia for children and adults aged 4 years and older with ...

Vykat XR is specifically indicated to address hyperphagia, or the abnormally strong sensation of hunger, which often leads to ...

Soleno Therapeutics has won US Food and Drug Administration (FDA) approval for diazoxide choline – which will be branded as ...

Soleno Therapeutics (SLNO) “announced that the FDA has approved VYKAT XR, diazoxide choline, extended-release tablets, previously referred to ...

Becoming the first treatment for rare genetic disorder Prader-Willi syndrome, breakthrough therapy drug DCCR (diazoxide choline) gained U.S. FDA approval as Vykat XR the evening before its March 27 ...

Soleno's shares soar in the premarket hours following the FDA approval of Vykat XR (diazoxide choline) for treating ...

Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi ...

Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares are trading higher Thursday after the company announced it secured FDA ...

Diazoxide 50mg/mL; chocolate-mint flavor; contains alcohol 7.25%. Diazoxide administered orally produces a prompt dose-related increase in blood glucose level, due primarily to an inhibition of ...